From a6ac1c4b4e15f37d00441346e5a0ddb03c30af01 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 3 May 2026 04:36:00 +0000 Subject: [PATCH] vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis - Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...-through-mesolimbic-dopamine-modulation.md | 7 ++++ ...uction-through-vta-dopamine-suppression.md | 9 ++++- entities/health/nct04199728-glp1-oud.md | 34 +++++++++++++++++++ ...on-scope-oud-nicotine-cocaine-synthesis.md | 5 ++- 4 files changed, 53 insertions(+), 2 deletions(-) create mode 100644 entities/health/nct04199728-glp1-oud.md rename inbox/{queue => archive/health}/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md (98%) diff --git a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md index c5838cf0d..bb8922284 100644 --- a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md +++ b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md @@ -81,3 +81,10 @@ Concurrent psychotropic medication use (antidepressants, benzodiazepines) shows **Source:** The Lancet 2026, EVOKE/EVOKE+ Phase 3 failure EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 CNS mechanism specificity. Semaglutide succeeds in addiction (VTA dopamine reward circuits) but fails in neurodegeneration (amyloid/tau pathways), demonstrating that GLP-1 receptor activation produces pathway-specific effects rather than broad neuroprotection. This supports the mesolimbic dopamine mechanism for addiction while ruling out generalized CNS benefit claims. + + +## Extending Evidence + +**Source:** NBC News/Pharmacy Times synthesis, April 2026 + +NBC News synthesis documents GLP-1 evidence across four substance use disorder categories: (1) OUD: liraglutide shows ~40% craving reduction in Phase 2 RCT, semaglutide reduces overdose risk in T2D+OUD comorbid population; (2) Nicotine: exenatide+NRT increases 6-week abstinence, but long-term findings mixed; (3) Cocaine/stimulants: preclinical only (liraglutide reduces methamphetamine intake in rats); (4) Population-level: GLP-1 users with pre-existing SUD show fewer ER visits, hospitalizations, deaths across substance categories (observational data with selection bias concerns). Evidence strength hierarchy: AUD > OUD > nicotine > cocaine. As of April 2026, 33 clinical trials active (15 AUD, 9 nicotine, 4 OUD, 4 cocaine). Critical limitation: all human evidence from patients with comorbid metabolic disease—efficacy without T2D/obesity comorbidity unknown. diff --git a/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md b/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md index e1525e931..497a2188b 100644 --- a/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md +++ b/domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md @@ -11,7 +11,7 @@ sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.m scope: causal sourcer: Hendershot CS et al. supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] -related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"] +related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"] --- # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression @@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio **Source:** Qeadan F et al., Addiction 2025 Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference. + + +## Extending Evidence + +**Source:** NBC News synthesis + Session 22 Science 2025 + +The VTA dopamine mechanism is shared across all substance use disorders, not AUD-specific. GLP-1 receptors in ventral tegmental area and nucleus accumbens reduce dopamine surge from substance exposure, attenuating reward salience. This explains why GLP-1 effects extend beyond alcohol to opioids, nicotine, and potentially cocaine. However, Session 22 Science 2025 paper showed VTA dopamine circuits adapt during repeat GLP-1 treatment (mice recover hedonic eating), suggesting efficacy may fade with long-term use for some reward circuits. diff --git a/entities/health/nct04199728-glp1-oud.md b/entities/health/nct04199728-glp1-oud.md new file mode 100644 index 000000000..1212374fc --- /dev/null +++ b/entities/health/nct04199728-glp1-oud.md @@ -0,0 +1,34 @@ +# NCT04199728: GLP-1 Receptor Agonist for Opioid Use Disorder + +**Type:** Clinical trial +**Phase:** 2 +**Status:** Active (as of April 2026) +**Intervention:** GLP-1 receptor agonist (specific drug not specified in source) +**Target:** Opioid Use Disorder (OUD) + +## Trial Context + +Part of broader GLP-1 substance use disorder research program. As of April 2026, 4 OUD trials active out of 33 total SUD trials. + +## Evidence Base + +**Liraglutide OUD data:** +- ~40% reduction in opioid craving in small randomized double-blind placebo-controlled residential study +- Phase 2 evidence only + +**Semaglutide OUD data:** +- Significantly reduced opioid overdose risk in 1-year follow-up for patients with comorbid T2D + OUD (real-world observational data) +- Cannot distinguish causal mechanism from selection effects + +**Mechanism:** GLP-1 receptors in ventral tegmental area (VTA) and nucleus accumbens reduce dopamine surge from opioid exposure, attenuating reward salience. + +**Critical limitation:** All human evidence from patients with comorbid metabolic disease. Efficacy for OUD without T2D/obesity comorbidity unknown and largely unstudied. + +## Timeline + +- **2026-04-28** — NBC News synthesis reports Phase 2 evidence for GLP-1 in OUD, no Phase 3 trials completed + +## Sources + +- NBC News/Pharmacy Times synthesis, April 2026 +- ClinicalTrials.gov NCT04199728 \ No newline at end of file diff --git a/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md b/inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md similarity index 98% rename from inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md rename to inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md index ad209a73c..f96e8fac5 100644 --- a/inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md +++ b/inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md @@ -7,10 +7,13 @@ date: 2026-04-28 domain: health secondary_domains: [] format: news-analysis -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-03 priority: medium tags: [GLP-1, addiction, opioid-use-disorder, nicotine, cocaine, substance-use-disorder, VTA-dopamine, reward-mechanism] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content